Table 2.

Clinical features of patients with interstitial lung disease

Subject	Age at HSCT (year)	Gender	Primary disease	Conditioning regimen, first HDCT, second HDCT	Biopsy findings	Symptom, time after HSCT (month)	CT findings	Outcome, time after HSCT (month)
1	2	F	MBL	1. CyM 2. BM	Interstitial fibrous thickening with lymphocytic infiltration	Dyspnea, chest discomfort 74	Subpleural thickening	Death 84
2	8	M	MBL	1. CT 2. CyM	Pleural thickening	Dyspnea 5	Interstitial thickening ground glass opacity	Death 15
3	1	F	NBL	1. CECy 2. TM	Interstitial fibrosis and inflammatory cell infiltration	Cough, dyspnea 16	Subpleural consolidation, ground glass opacity	Death 39
4	3	F	NBL	1. CECy 2. TM	Interstitial fibrosis and inflammatory cell infiltration	Cough, dyspnea 28	Pleural and interstitial thickening ground glass opacity	Death 46
5	2	F	NBL	1. CECy 2. TM	Interstitial fibrosis and patch lymphocytic infiltration	Cough, dyspnea 32	Fibrotic change with volume reduction, subpleural ground glass opacity	Death 62
6	3	F	NBL	1. CECy 2. TM	Interstitial thickening	Cough, dyspnea 50	Perifissural, subpleural consolidation, uneven aeration	Alive 63
7	2	F	NBL	1. CECy 2. CEM	Interstitial fibrosis and lymphocytic infiltration	Cough, dyspnea 7	Interstitial septal thickening, ground glass opacity	Death 23
8	2	F	NBL	1. CECy 2. TM	Fibrotic scar	Dyspnea 74	Patchy supleural consolidation, interstitial thickening	Alive 96

BM, Busulfan and melphalan; CECy, carboplatin, etoposide and cyclophosphamide; CEM, carboplatin, etoposide and melphalan; CT, computed tomography; CTE, carboplatin, thiotepa and etoposide; CyM, cyclophosphamide and melphalan; MBL, medulloblastoma; NBL, neuroblastoma; TM, thiotepa and melphalan.